Screening and detection application of secretory immune checkpoint FGL1 aptamer
FGL1 nucleic acid aptamer was screened through the protein SELEX method separated by agarose microbeads and a molecular beacon probe was constructed, which solved the problem of FGL1 detection in liver cancer, achieved specific identification and detection of FGL1 in liver cancer cells, and predicted PD-1 /PD-L1 checkpoint inhibitor efficacy provides new guidance for the immune efficacy of liver cancer.
Patent Information
- Application Number
- CN202411179043.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-12
AI Technical Summary
The clinical response rate of existing PD-1/PD-L1 inhibitors is not high and is accompanied by side effects of immunotoxicity. New immune checkpoints need to be explored to predict the immunotherapy effect of PD-1/PD-L1, especially in the treatment of liver cancer. , it is difficult to accurately detect FGL1 expression levels to guide immune medication.
The protein SELEX method isolated from agarose microbeads was screened for excellent performance FGL1 nucleic acid aptamer, and a molecular beacon probe based on this aptamer was constructed to achieve specific identification and detection of FGL1 in liver cancer cells.
This technical solution provides a high affinity and specific FGL1 nucleic acid aptamer and molecular beacon probe that can be chemically synthesized in vitro, easily designed and labeled, and is used for accurate detection of FGL1 in liver cancer cells, predicting PD-1/PD -The efficacy of L1 checkpoint inhibitors provides new guidance for the immune efficacy of liver cancer.
Smart Images

Figure CN118931909A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to nucleic acid aptamers of secretory immune checkpoint FGL1 and molecular beacon probe technology thereof, and specifically to the screening and detection application of nucleic acid aptamers of secretory immune checkpoint FGL1. Background Art
[0002] At present, the clinical response rate of immune checkpoint inhibitors represented by PD-1 / PD-L1 inhibitors is not high, and they are accompanied by immune toxic side effects. In order to reduce the risk of treatment and maximize the benefits of patients, it is necessary to predict whether patients will respond to immune drugs. Therefore, it is urgent to explore new immune checkpoints and use them to predict the efficacy of PD-1 / PD-L1 immune therapy.
[0003] FGL1 (Fibrinogen Like Protein 1), liver fibrinogen-related gene-1, is a proliferation and metabolism-related factor secreted by the liver. The latest studies have shown that FGL1, as a new LAG3 ligand, can bind to LAG3 to form a new immune checkpoint pathway independent of PD-1 / PD-L1, leading to T cell exhaustion and tumor immune escape. In addition, studies have reported that FGL1-positive liver cancer cells and high levels of FGL1 in plasma are associated with poor prognosis of liver cancer. Therefore, sensitive FGL1 detection probes can be developed for efficient detection of FGL1 expression levels.
[0004] Aptamers, also known as chemical antibodies, are small and flexible, have little steric interference, high recognition efficiency, and are non-immunogenic. As a molecular recognition tool with excellent performance, they show great application prospects in the field of immune checkpoint detection. Therefore, if high-performance FGL1 aptamer molecules can be developed, they will be used to detect FGL1 in liver cancer cells and accurately predict the efficacy of PD-1 / PD-L1 checkpoint inhibitors, bringing new hope to the research on liver cancer immune drug guidance. Summary of the invention
[0005] The purpose of the present invention is to provide an FGL1 nucleic acid aptamer with excellent performance, and to provide a molecular beacon probe based thereon, which can specifically detect FGL1 in liver cancer cells. The FGL1 nucleic acid aptamer provided in the present invention is obtained by screening through a protein SELEX method based on agarose microbead separation, has high affinity and specificity, can be chemically synthesized in vitro, is easy to design and program, and is convenient for labeling and modification; a molecular beacon probe is constructed based on the obtained FGL1 aptamer to achieve specific recognition of FGL1 in liver cancer cells. The FGL1 aptamer molecular beacon probe provided by the present invention can be used as a molecular detection tool for FGL1, and is expected to be used in clinical detection of FGL1 expression levels to predict the efficacy of PD-1 / PD-L1 checkpoint inhibitors.
[0006] The technical solution for achieving the purpose of the present invention is:
[0007] The secretory immune checkpoint FGL1 nucleic acid aptamer, the FGL1 nucleic acid aptamer is the nucleotide sequence shown in SEQ ID No.1, SEQ ID No.1, named YL2:
[0008] 5′-ACCGACCGTGCTGGACTCATGGTTGTTAGGTTTGTTCTGGGGTGGGTGGTTGGGGAAGACAACTATGAGCGAGCCTGGCG-3′.
[0009] The FGL1 nucleic acid aptamer is a nucleotide sequence shown in SEQ ID No.1 truncated sequence SEQ ID No.2, SEQ ID No.2, named YL2D:
[0010] 5′-ATGGTTGTGGGTGGGGTGGGGGTGGGGGACAACTAT-3′.
[0011] The FGL1 molecular beacon probe was constructed using the nucleotide sequence shown in SEQ ID No.2. The FGL1 molecular beacon probe was the nucleotide sequence shown in SEQ ID No.3, SEQ ID No.3, named MB-YL2D:
[0012] 5′-FAM-ATGGTTGTGGGTGGGGTGGGGGTGGGGGACAACTATGGG-BHQ1-3′.
[0013] The FGL1 nucleic acid aptamer also includes a mutant or a truncated sequence of the nucleotide sequence shown in SEQ ID No.1 or SEQ ID No.2.
[0014] The FGL1 nucleic acid aptamer mutant is a sequence having more than 80% homology to the nucleotide sequence shown in SEQ ID No.1 or SEQ ID No.2.
[0015] The FGL1 molecular beacon probe also includes a mutant or a truncated sequence of the nucleotide sequence shown in SEQ ID No.3.
[0016] The FGL1 molecular beacon probe mutant is a sequence having more than 80% homology to the nucleotide sequence shown in SEQ ID No.3.
[0017] A method for screening nucleic acid aptamers for the secretory immune checkpoint FGL1 is to use a protein SELEX method based on agarose microbead separation-laser confocal imaging analysis for screening.
[0018] The application of the secretory immune checkpoint FGL1 aptamer and its molecular beacon probe for specific detection of FGL1 includes at least one of the following:
[0019] 1) Application of laser confocal imaging and microplate reader fluorescence detection of FGL1 in liver cancer cells and its secretion;
[0020] 2) Application of laser confocal imaging and microplate reader fluorescence detection of FGL1 in liver cancer tissue or plasma;
[0021] 3) Application of FGL1 nucleic acid aptamer in predicting the efficacy of tumor immunotherapy drugs;
[0022] 4) Application of FGL1 nucleic acid aptamer in the preparation of tumor targeting drugs and immunotherapy drugs.
[0023] Compared with the prior art, this technical solution has the following advantages:
[0024] 1) The FGL1 nucleic acid aptamer of this technical solution is screened by a protein SELEX method based on agarose microbead separation, which is simple and rapid. Nucleic acid aptamers have the characteristics of being able to be chemically synthesized in vitro, easy to design and program, and convenient for labeling and modification, and have broad application prospects.
[0025] 2) The FGL1 aptamer molecular beacon probe of this technical solution realizes the specific recognition and detection analysis of FGL1 in liver cancer cells, and is expected to be used as a molecular detection tool for FGL1 levels in clinical samples (liver cancer tissue, plasma) to accurately predict the efficacy of PD-1 / PD-L1 checkpoint inhibitors, bringing new hope to the research on accurate prediction of liver cancer immune efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Laser confocal imaging was used to monitor the aptamer screening and enrichment process. As the number of screening rounds increased, the fluorescence intensity of the enriched library binding to FGL1-Beads increased significantly ( Figure 1 A), while the fluorescence intensity of the control microspheres (IgG1-Beads / Protein A-Beads) did not increase ( Figure 1 B, C), where 10 rounds of enrichment reached a plateau.
[0027] Figure 2 Laser confocal imaging was used to investigate the binding ability of the five candidate sequences YL1, YL2, YL3, and YL4 obtained by sequencing to the eukaryotic proteins YL5 and FGL1. All five candidate sequences were able to bind to FGL1-Beads ( Figure 2 A), but not binding to control microspheres ( Figure 2 B, C), among which YL2 has the strongest binding.
[0028] Figure 3Laser confocal imaging was used to investigate the binding ability of the YL2 series of truncated sequences to the FGL1 eukaryotic protein. All five truncated nucleic acid aptamers were able to bind to FGL1-Beads ( Figure 3 A), but no binding with control microspheres ( Figure 3 B, C). Taking into account the complementary base pairs and binding strength of the probe hairpin part, YL2D was selected as the optimal truncated sequence and used to construct the FGL1 aptamer molecular beacon probe.
[0029] Figure 4 The dissociation constant of the YL2D truncated sequence against the FGL1 eukaryotic protein is 65.65±8.7 nM.
[0030] Figure 5 The ability of FGL1 aptamer molecular beacon probe MB-YL2D to detect FGL1 eukaryotic protein without washing was investigated for laser confocal imaging. In the absence of washing, MB-YL2D can specifically recognize FGL1-Beads and has good selectivity (it does not bind to control microspheres and eukaryotic IL18BP-Beads).
[0031] Figure 6 Laser confocal imaging was used to confirm that the constructed FGL1-overexpressing human liver cancer HepG2 cells expressed FGL1.
[0032] Figure 7 The ability of FGL1 aptamer molecular beacon probe to detect FGL1 in human hepatoma cell HepG2 was investigated by laser confocal imaging. Human hepatoma cell HepG2 is a constructed FGL1 overexpression cell, and FGL1 expression has been confirmed by FGL1 antibody. DETAILED DESCRIPTION
[0033] The present invention is further described below with reference to the accompanying drawings and embodiments, but the present invention is not limited thereto.
[0034] Example 1: Screening of FGL1 nucleic acid aptamers:
[0035] 1) Nucleic acid library and primers:
[0036] Random nucleic acid library (consisting of 80 bases, including a fixed sequence of 19 bases at each end and a random sequence of 42 bases in the middle):
[0037] Initial library (SEQ ID No 4):
[0038] 5′-ACCGACCGTGCTGGACTCA(N) 42 ACTATGAGCGAGCCTGGCG-3′
[0039] Forward primer SEQ ID No 5: 5′-FAM-ACCGACCGTGCTGGACTCA-3′;
[0040] Rear primer SEQ ID No 6: 5′-Biotin-CGCCAGGCTCGCTCATAGT-3′;
[0041] 2) Library preprocessing:
[0042] 6 nmol of the initial library was dissolved in binding buffer (PBS containing 2.5 mmol / L MgCl2, pH 7.4) and subjected to denaturation treatment: 95°C for 5 min, then placed on ice for 5 min, and finally placed at room temperature for 5 min;
[0043] 3) coupling FGL1 protein and IgG1 protein to Protein A-Beads;
[0044] Based on the affinity interaction between Fc and Protein A, the FGL1 (Fc tag) eukaryotic protein was fixed on Protein A agarose microspheres (Protein A-Beads) to obtain FGL1 protein agarose microspheres (FGL1-Beads); IgG1 protein was coupled to Protein A-Beads to obtain IgG1 agarose microspheres (IgG1-Beads);
[0045] 4) Positive screening:
[0046] The pre-treated initial library obtained in step 2) is incubated with FGL1-Beads at 25° C. for 40 min; after the incubation is completed, the DNA sequences not bound to the FGL1-Beads are separated and removed, and the FGL1-Beads are washed with binding buffer PBS to elute the nucleic acid sequences that remain bound to the target, thereby obtaining the first round of pre-enrichment library;
[0047] 5) Counter-screening:
[0048] In step 4), when the third round of screening is carried out, a counter-screening process needs to be added. The specific operation is as follows: the processed pre-enrichment library of the previous round is incubated with IgG1-Beads / Protein A-Beads at 25°C for 15 minutes for counter-screening to exclude non-specifically bound nucleic acid sequences;
[0049] 6) Pre-amplification of library:
[0050] The pre-enriched library obtained by screening was pre-amplified, and the amplification system was: sterile water 182.5μL, 10×tagBuffer 25μL, 2.5mM dNTPs 20μL, 10uM upstream primer 10μL, 10uM downstream primer 10μL, Taq enzyme 2.5μL; amplification conditions were: 94℃, 5min; 94℃, 30s; 58℃, 30s, 72℃, 30s, after 8 cycles, 72℃, 5min; 7) Use the pre-amplification product as a template for large-scale amplification:
[0051] Characterize the DNA products of each cycle by agarose gel electrophoresis, select the optimal number of amplification cycles for amplification, and obtain the amplification product. The amplification system is the same as the primers used in the pre-amplification system in step 6), and the amplification product obtained in each round is the enrichment library;
[0052] 8) Preparation of single-stranded DNA library:
[0053] The PCR amplification product in step 7) is reacted with streptavidin agarose microspheres at 25°C for 20 minutes; then the double-stranded DNA is denatured and melted using 0.1 mol / L sodium hydroxide, desalted and filtered through a 3K ultrafiltration tube, and purified to obtain a single-stranded DNA library for the next round of screening;
[0054] 9) Cycle screening:
[0055] Using 1 nmol of the secondary single-stranded DNA library, repeat the screening in steps 2) to 8), and gradually reduce the amount of library and FGL1-Beads input in subsequent rounds, and gradually increase the amount of IgG1-Beads / Protein A-Beads input and the number of washes to enhance the screening intensity;
[0056] 10) Characterization of enrichment process:
[0057] After 10 rounds of screening and enrichment, the enriched library was incubated with FGL1-Beads at 25°C for 30 min. After incubation, the library was washed twice with binding buffer and analyzed by laser confocal imaging. Figure 1 As shown, starting from the 7th round, the enriched library began to bind to FGL1-Beads and did not bind to IgG1-Beads / Protein A-Beads. Finally, the 10-round enriched libraries with the strongest binding were selected for high-throughput sequencing.
[0058] Example 2: Determination of the optimal FGL1 aptamer
[0059] Through comparison analysis, five candidate sequences, YL1, YL2, YL3, YL4 and YL5, were selected, and then laser confocal imaging was used to investigate the binding ability of the five candidate sequences with the FGL1 eukaryotic protein. Figure 2 As shown, all five candidate sequences can bind to FGL1-Beads, but not to IgG1-Beads / Protein A-Beads, among which YL2 (SEQ ID No. 1) has the strongest binding. The results show that after 10 rounds of enrichment, FGL1 aptamer YL2 was obtained.
[0060] Next, NUPACK was used to simulate the secondary structure of the YL2D aptamer, and its base composition and spatial structure were analyzed. After reasonable truncation optimization, a series of truncated sequences, YL2A, YL2B, YL2C, YL2D, and YL2E, were obtained. Laser confocal imaging was then used to investigate the binding ability of the five truncated sequences with the FGL1 eukaryotic protein. Figure 3 As shown in the figure, all five truncated sequences can bind to FGL1-Beads, but none of them can bind to IgG1-Beads / Protein A-Beads. Considering the complementary pair number of hairpin bases and the binding strength, YL2D (SEQ ID No. 2) was selected as the optimal truncated sequence. In addition, the dissociation constant of YL2D aptamer was 65.65±8.7nM ( Figure 4 ), so YL2D was selected to construct the molecular beacon probe.
[0061] Example 3: Construction and performance characterization of FGL1 aptamer molecular beacon probe
[0062] Under the premise of ensuring that the original affinity and selectivity of YL2D nucleic acid aptamer remain basically unchanged, the fluorescent group FAM is labeled at the 5' end of the sequence, and three G bases are introduced at the 3' end of the sequence and labeled with the quenching group BHQ1 to construct the FGL1 aptamer molecular beacon probe MB-YL2D (SEQ ID No.3). MB-YL2D retains the targeting function of the aptamer and has the excellent fluorescent labeling characteristics of the molecular beacon. It can specifically detect the FGL1 eukaryotic protein without the need for conventional washing steps. The results are shown in Figure 3. Figure 5 As shown, the molecular probe MB-YL2D can accurately identify FGL1-Beads without background interference without washing, and has good specificity and selectivity (it does not recognize IgG1-Beads / Protein A-Beads).
[0063] Example 4: FGL1 aptamer molecular beacon probe sensitively detects FGL1 in liver cancer cells
[0064] Human hepatoma cell line HepG2 is a constructed FGL1 overexpressing cell line. FGL1 expression has been confirmed using FGL1 antibody ( Figure 6 ). Then, the FGL1 aptamer molecular beacon probe was used to detect FGL1 in liver cancer cells HepG2 by laser confocal imaging without washing, and MB-Control was used as a negative control. Figure 7 As shown, compared with the MB-Control group, the MB-YL2D group could specifically detect FGL1 in liver cancer cells.
Claims
1. A secretory immune checkpoint FGL1 aptamer, characterized in that: The FGL1 nucleic acid aptamer has the nucleotide sequence shown in SEQ ID No.
1.
2. The secretory immune checkpoint FGL1 nucleic acid aptamer according to claim 1, characterized in that The FGL1 nucleic acid aptamer is a nucleotide sequence shown in the truncated sequence of SEQ ID No.1 and SEQ ID No.
2.
3. The secretory immune checkpoint FGL1 nucleic acid aptamer according to claim 2, characterized in that The FGL1 molecular beacon probe is constructed using the nucleotide sequence shown in SEQ ID No.2, and the FGL1 molecular beacon probe is the nucleotide sequence shown in SEQ ID No.
3.
4. The use of the secretory immune checkpoint FGL1 aptamer according to claim 1, characterized in that: The application includes at least one of the following: 1) Application of laser confocal imaging and microplate reader fluorescence detection of FGL1 in liver cancer cells and its secretion; 2) Application of laser confocal imaging and microplate reader fluorescence detection of FGL1 in liver cancer tissue or plasma; 3) Application of FGL1 nucleic acid aptamer in predicting the efficacy of tumor immunotherapy drugs; 4) Application of FGL1 nucleic acid aptamers in the preparation of tumor-targeted drugs and immunotherapy drugs.
